Titanovo Logo
Back to Cell Types

SU-DHL-10Homo sapiens (Human)Cancer cell line

Also known as: DHL10, Stanford University-Diffuse Histiocytic Lymphoma-10, SuDHL 10, SUDHL-10, Sudhl10, SUDHL10, Su-DHL-10

🤖 AI SummaryBased on 12 publications

Quick Overview

SU-DHL-10 is a human B-cell lymphoma cell line used in cancer research.

Detailed Summary

SU-DHL-10 is a human B-cell lymphoma cell line derived from a patient with diffuse large B-cell lymphoma (DLBCL). It is commonly used in research to study the molecular mechanisms of lymphoma and to test the efficacy of new therapeutic agents. This cell line has been utilized in studies involving BCL-2 inhibition, venetoclax resistance, and the role of MCL1 in lymphoma progression. SU-DHL-10 is part of a panel of cell lines used to investigate the genetic and molecular characteristics of DLBCL, contributing to the understanding of cancer biology and the development of targeted therapies.

Research Applications

BCL-2 inhibition studiesVenetoclax resistance mechanismsMCL1 role in lymphoma progressionGenetic and molecular characterization of DLBCL

Key Characteristics

Expresses high levels of BCL-2Used in studies of apoptosis and drug resistancePart of a panel for DLBCL research
Generated on 6/17/2025

Basic Information

Database IDCVCL_1889
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age25
Age CategoryAdult
SexMale

Disease Information

DiseaseDiffuse large B-cell lymphoma
LineageLymphoid
SubtypeDiffuse Large B-Cell Lymphoma, NOS
OncoTree CodeDLBCLNOS

DepMap Information

Source TypeDSMZ
Source IDACH-000271_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53c.994-1G>AHomozygousSplice acceptor mutationUnknown, Unknown
MutationSimplePTENp.Asp162His (c.484G>C)Homozygous-Unknown, Unknown, PubMed=9787181
MutationSimplePTENp.Tyr68His (c.202T>C)Homozygous-Unknown, Unknown, PubMed=9787181

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
10,13
D13S317
10,11
D16S539
10,11
D18S51
17
D19S433
13,15
D21S11
31
D2S1338
17,23
D3S1358
15,16
D5S818
11,12
D7S820
8,11
D8S1179
8
FGA
22,23
Penta D
9,11
Penta E
16,17
TH01
8,9.3
TPOX
8
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOIPubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

DOIPubMedPMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOIPubMedPMC

Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.

Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.

Clin. Cancer Res. 24:3967-3980(2018).

DOIPubMed

Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.

Pham L.V.

Oncotarget 9:346-360(2018).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.

Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.

Leuk. Lymphoma 57:1015-1020(2016).

DOIPubMed

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.

O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.

J. Virol. 89:713-729(2015).

DOIPubMedPMC

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.";

Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.

Leukemia 27:1381-1390(2013).

DOIPubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Kutok J.L., Shipp M.A.

Blood 116:3268-3277(2010).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.

Nature 463:88-92(2010).

DOIPubMedPMC

Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.

Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.

Int. J. Cancer 125:212-221(2009).

DOIPubMed

Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Robetorye R.S., Aguiar R.C.T.

Blood 113:6681-6690(2009).

DOIPubMedPMC

Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.

Uppenkamp M.J., Nowrousian M.R., Seeber S., Opalka B.

Br. J. Haematol. 91:350-354(1995).

DOIPubMed

PTEN gene alterations in lymphoid neoplasms.";

Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.

Blood 92:3410-3415(1998).

DOIPubMed

Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.

Aizawa Y., Ueda R., Seto M.

Jpn. J. Cancer Res. 89:712-718(1998).

DOIPubMedPMC

Histiocytic lymphoma cell lines: immunologic and cytogenetic studies.

Hecht F.

Cancer Genet. Cytogenet. 14:205-218(1985).

DOIPubMed

Phenotypic and genotypic characterization of 14 leukemia and lymphoma cell lines with 11q23 translocations.

Ueda R., Nakazawa S.

Leuk. Res. 16:1155-1163(1992).

DOIPubMed

Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines.

Epstein A.L., Kaplan H.S.

Cancer Res. 39:1748-1759(1979).

PubMed

Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines.

Epstein A.L., Levy R., Kim H., Henle W., Henle G.S., Kaplan H.S.

Cancer 42:2379-2391(1978).

DOIPubMed

Biology of the human malignant lymphomas. III. Intracranial heterotransplantation in the nude, athymic mouse.

Epstein A.L., Herman M.M., Kim H., Dorfman R.F., Kaplan H.S.

Cancer 37:2158-2176(1976).

DOIPubMed

Biology and virology of the human malignant lymphomas: 1st Milford D. Schulz Lecture.

Kaplan H.S., Goodenow R.S., Gartner S., Bieber M.M.

Cancer 43:1-24(1979).

DOIPubMed

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI

Web Resources

tcpaportal.org